GUIDELINE AND CONSENSUS

Organization of Bone Sarcoma Care: A Cross-Sectional European Study

Louren Matthias Goedhart, MD¹, Andreas Leithner, MD, PhD², Paul Christiaan Jutte, MD, PhD¹

¹Department of Orthopaedic surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands and
²Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria

Objective: To assess organization of care in several bone sarcoma centers in Europe affiliated with the European Musculoskeletal Oncology Society (EMSOS) for comparison and to identify potential improvements in organization of care.

Methods: Data for this observational cross-sectional study was obtained through healthcare professionals affiliated to EMSOS. The authors formulated 10 questions regarding organization of care. The questions were focused on guidance, multidisciplinary decision-making, and data storage. A digital questionnaire was synthesized and included quality control. The digital questionnaire was sent to 54 representative members of EMSOS. We did not receive responses from 29 representative countries (53.7%) after one digital invitation and two digital reminders.

Results: We received data from 25 representatives of bone sarcoma centers from 17 countries across Europe (46.3%). Authorization to perform oncological care in a bone sarcoma center was government issued in 41.2% of cases and based on expertise without governmental influence in 52.9% of cases. In 64.7% of the countries, a national bone tumor guideline regarding for diagnosis and treatment is used in oncological care. A national bone tumor board for extensive case evaluation including classification and advice for treatment is available for 47.1% of the countries. All participating bone sarcoma centers have a mandatory local multidisciplinary meeting before the start of treatment; in 84.0% this meeting takes place once a week. During this multidisciplinary meeting a median of 15 cases (range, 4–40 cases) are discussed. In terms of storage of oncological data, a local registry is used in eight countries (47.1%). A national registry is used in eight countries (47.1%).

Conclusions: A national bone tumor board gives bone sarcoma centers with little adherence the opportunity to gain knowledge from a more experienced team. Centralization of care in a bone sarcoma center is important to lower incidences. The optimal size for a bone sarcoma center in terms of patient adherence is not known at present.

Key words: Bone sarcoma; Centralization; Organization of care

Introduction

High-grade bone sarcomas are aggressive tumors with a high potential of metastasis. Diagnosis and treatment of these neoplasms is challenging due to low incidences¹⁻⁵.

Therefore, centralization of sarcoma care is important in order to realize a multidisciplinary approach by an experienced team⁶,⁷. Nowadays, the majority of patients with a primary bone sarcoma are diagnosed and treated in a bone sarcoma center. A few dozen bone sarcoma centers with expertise are scattered across Europe. However, as for differences in nationwide organization of care, the approach towards diagnosis and treatment differs between these hospitals. Further differences are seen in terms of patient adherence to bone sarcoma centers due to centralization of care. Based on a single study, treatment in a bone sarcoma center was associated with higher survival for high-grade osteosarcoma patients⁸. However, this association was not seen for high-grade chondrosarcoma and Ewing sarcoma patients. Furthermore, the optimal size for a bone sarcoma center in terms of patient adherence is not known at this moment.

Address for correspondence: Louren Matthias Goedhart, MD, Resident Orthopaedic Surgery, University Medical Center Groningen, Postbus 30.001, RB Groningen, The Netherlands 9700 Tel: +31(0)50 361 9705; Fax: +31(0)50 361 1737; Email: l.m.goedhart@umcg.nl

Disclosure: The authors declare that they have no conflicts of interest and did not receive funding for this study.

Received 17 January 2020; accepted 30 April 2020

Orthopaedic Surgery 2020;12:1030-1035 • DOI: 10.1111/os.12716

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
The European Musculoskeletal Oncology Society (EMSOS) aims to promote advances in science, disseminate knowledge, and promote mutual collaboration for bone sarcoma care between the different affiliated bone sarcoma centers.

This study aims to assess organization of care in several bone sarcoma centers in Europe affiliated with EMSOS for comparison and improvement of knowledge.

**Methods**

The European Musculoskeletal Oncology Society (EMSOS) was founded in 1987. The particular purpose of EMSOS is to facilitate a network for different specialists and institutes in order to improve treatment of musculoskeletal tumors. This is realized by collaborative research projects and disseminating knowledge through an annual congress.

Data for this observational cross-sectional study was obtained through healthcare professionals affiliated with EMSOS. The authors formulated 10 questions regarding organization of care and produced a digital questionnaire, which is displayed in the appendix. The questions were focused on guidance, multidisciplinary decision-making, and data storage. The digital questionnaire was not validated. EMSOS members were approached as representatives from all over Europe. These representatives were asked to return this digital questionnaire. A flowchart of the study design was displayed in Fig. 1. Observational research among healthcare professionals does not fall under the scope of the Dutch Act on Medical Scientific Research involving Human Beings (WMO).

Analyses were performed using IBM SPSS Statistics for Windows (Version 23.0, United States) and Microsoft Excel 2013 (United States).

![Fig. 1 Flowchart of the study design.](image)

**Results**

A digital questionnaire was sent to 54 representative members of EMSOS and we received a response from 25 representatives (46.3%) from 17 countries after one digital invitation and two digital reminders. These representatives were acknowledged as the EMSOS study group. The geographical dispersion across Europe of responding bone sarcoma centers was displayed in Fig. 2. Questionnaire output data regarding bone sarcoma centers per country were displayed in Table 1.

**Guidance**

Authorization to perform oncological care in a bone sarcoma center was government issued in the Netherlands, the United Kingdom, Norway, Sweden, Finland, Poland, and Ukraine (41.2%). Authorization based on expertise without governmental influence was seen in Belgium, France, Spain, Italy, Austria, Switzerland, Slovenia, Serbia, and Turkey (52.9%). A lack of consensus towards authorization of bone sarcoma centers was seen in Germany, there are not a defined number of bone sarcoma centers in this country. In 64.7% of the countries, a national bone tumor guideline regarding diagnosis and treatment is used in oncological care. In Belgium, Italy, Finland, Austria, Serbia, and Turkey, local hospital guidelines are used for diagnosis and treatment (35.3%). Several (national) bone tumor guidelines, obtained through the questionnaire, are displayed in the appendix.

**Multidisciplinary Decision Making**

A national bone tumor board for extensive case evaluation including classification and advice for treatment is available in the Netherlands, the United Kingdom, France, Sweden, Finland, Poland, Slovenia, and Serbia (47.1%). All participating bone sarcoma centers have a mandatory local multidisciplinary meeting before the start of treatment; in the vast majority this meeting takes place once a week (84.0%). During this multidisciplinary meeting a median of 15 cases (range, 4–40 cases) are discussed. Regarding referral towards and treatment in a bone sarcoma center, most countries had percentages in the upper quartiles as shown in Table 1. Lower referral percentages were seen in Belgium (50%), Ukraine (50%), and Turkey (5%). With regards to treatment in a bone sarcoma center, relatively low treatment percentages were seen in Spain (30%), Ukraine (30%), and Turkey (20%).

**Data storage**

A local registry for oncological data is used in Belgium, Germany, Spain, Italy, Norway, Finland, Switzerland, and Serbia (47.1%). A national registry is used in the Netherlands, the United Kingdom, France, Sweden, Austria, Poland, Slovenia, and Ukraine (47.1%). Bone tumors are not registered in Turkey (5.8%).
Dedicated health care professionals all over Europe perform bone sarcoma care. This is the first study to provide cross-sectional data regarding organization of bone sarcoma care in Europe. A wide range of centralization across Europe was identified. Limitations of this study are clear because of the observational concept. Furthermore, the questionnaire we used was not validated. Finally, although the respondents represent a large proportion of Europe, the response rate of 46.3% could have led to response bias.

The basis on which oncological care in a bone sarcoma center is performed differs.

Most bone sarcoma centers are authorized based on expertise, and government authorization has been issued in the countries where the government has extensive responsibilities for national health care. In a considerable number of countries bone tumor guidelines are issued for diagnostic work-up, referral, and treatment. We believe that these guidelines are a valuable instrument for the clinicians. A recent development is that the European Commission launched an initiative for European Reference Networks (ERN) to create a network of excellence in clinical practice. These networks aim to facilitate discussion on and improve care of complex or rare diseases. Furthermore, essential requirements for quality cancer care for soft-tissue and bone sarcoma in adults were defined by the European CanCer Organization (ECCO). Partially based on these developments, a survey among Italian oncological health care professionals resulted in a set of minimum requirements needed to define a referral center for rare cancers.

An interesting finding from our study is the lack of consensus towards authorization of bone sarcoma centers in

---

**Fig. 2** Geographical dispersion across Europe of responding bone sarcoma centres. 1. Netherlands: University Medical Center Groningen, Leiden University Medical Center. 2. Belgium: Jules Bordet Institute Brussels. 3. Germany: Medical Center of the University of Munich, Stuttgart Cancer Center Olghospital. 4. United Kingdom: University College Hospital London, Royal Orthopedic Hospital Birmingham. 5. France: Limoges Teaching Hospital, University Hospital Hotel-Dieu Nantes, Hospital Cochin Paris. 6. Spain: Hospital Universitario de Bellvitge Barcelona, Hospital Universitario La Paz Madrid. 7. Italy: Centro Traumatologico Ortopedico Florence, Regina Elena National Cancer Institute Rome, Cancer Institute G. Pascal Foundation Naples. 8. Norway: Oslo University Hospital. 9. Sweden: Karolinska Hospital Stockholm. 10. Finland: Helsinki University Central Hospital. 11. Austria: Medical University of Graz. 12. Switzerland: Balgrist University Hospital Zürich. 13. Poland: Pomeranian Medical University of Szczecin. 14. Slovenia: Ljubljana University Medical Centre. 15. Serbia: Institute for Oncology and Radiology Belgrade. 16. Ukraine: National Cancer Institute Kiev. 17. Turkey: Acibadem Maslak Hospital Istanbul.
### TABLE 1 Questionnaire output data regarding bone sarcoma centres per country

| Country      | Number of bone sarcoma centres | Million inhabitants in 20189 | Million inhabitants per bone sarcoma centre | Authorisation basis | Bone tumor guideline | National bone tumor board | Number of cases discussed per week in local meeting | Referral to a bone sarcoma centre (%) | Treatment in a bone sarcoma centre (%) | Registry for oncological data |
|--------------|--------------------------------|-----------------------------|---------------------------------------------|---------------------|----------------------|--------------------------|-----------------------------------------------|-------------------------------------|--------------------------------------|-----------------------------------|
| Netherlands  | 4                              | 17.15                       | 4.28                                        | Government          | National             | Yes                      | 25–30                                         | 90                                  | 98                                   | National                         |
| Belgium      | 5                              | 11.57                       | 2.31                                        | Expertise           | Local                | No                       | 12                                            | 50                                  | 90                                   | Local                            |
| Germany      | Not clear*                     | 80.46                       | Not clear*                                  | Not clear*          | National             | No                       | 5–20                                          | Not clear*                          | Not clear*                          | Local†                           |
| United Kingdom| 5                              | 65.11                       | 13.02                                       | Government          | National             | Yes                      | 40                                            | 90                                  | 100                                  | National                         |
| France       | 12                             | 67.36                       | 5.61                                        | Expertise           | National             | Yes                      | 15–40                                         | 90                                  | 98                                   | National                         |
| Spain        | 10                             | 49.33                       | 4.93                                        | Expertise           | National             | No                       | 6–10                                          | 70                                  | 30                                   | Local                            |
| Italy        | 10                             | 62.25                       | 6.22                                        | Expertise           | Local                | No                       | 10–15                                         | 90                                  | 95                                   | Local                            |
| Norway       | 2                              | 5.37                        | 2.69                                        | Government          | National             | No                       | 10                                            | 90                                  | 100                                  | Local                            |
| Sweden       | 3                              | 10.04                       | 3.35                                        | Government          | National             | Yes                      | 20                                            | 95                                  | 95                                   | National                         |
| Finland      | 4                              | 5.54                        | 1.38                                        | Government          | Local                | Yes                      | 25                                            | 90                                  | 99                                   | Local                            |
| Austria      | 4                              | 8.79                        | 2.19                                        | Expertise           | Local                | No                       | 15                                            | 70                                  | 90                                   | National                         |
| Switzerland  | 5                              | 8.29                        | 1.66                                        | Expertise           | National             | No                       | 12                                            | 95                                  | N/A                                 | Local                            |
| Poland       | 5                              | 38.42                       | 7.68                                        | Government          | National             | Yes                      | 4                                             | 70                                  | 80                                   | National                         |
| Slovenia     | 1                              | 2.10                        | 2.10                                        | Expertise           | National             | Yes                      | 12                                            | N/A                                 | 95                                   | National                         |
| Serbia       | 1                              | 7.08                        | 7.08                                        | Expertise           | Local                | Yes                      | 10                                            | 70                                  | 80                                   | Local                            |
| Ukraine      | 4                              | 43.95                       | 10.98                                       | Government          | National             | No                       | 4                                             | 50                                  | 30                                   | National                         |
| Turkey       | 5                              | 81.26                       | 16.25                                       | Expertise           | Local                | No                       | 20                                            | 5                                  | 20                                  | No registry                      |

N/A, not available; * In Germany bone sarcoma centres are not defined, therefore it is not clear where bone sarcoma patients are treated in this country; † Cooperative German-Austrian-Swiss Osteosarcoma Study Group (COSS) and Cooperative German-Austrian-Swiss Ewing sarcoma Study Group (CESS) are multinational initiatives for registration of oncological data.
Germany, as shown in Table 1. Germany is clearly different from the other countries regarding its organization and centralization. Until now, a definition of a bone sarcoma center has never been developed in Germany, resulting in decentralization of bone sarcoma care towards treatment centers.

Decentralization of bone sarcoma care in a country could have adverse effects in terms of delay in diagnosis, misdiagnosis, and inappropriate treatment. Delay in diagnosis in high-grade bone sarcomas from symptoms until the start of the treatment has been described in the literature. Delay is inevitable, but minimizing delay using clear guidelines and referral patterns seems judicious. As mentioned earlier, assessment of radiology and histology by an experienced team is essential for a good prognosis in chondrosarcoma. Furthermore, misdiagnosis and subsequent inappropriate treatment resulted in inferior outcomes in osteosarcoma. For Ewing sarcoma, inadequate surgical margins are significantly correlated with inferior outcome. A study regarding soft-tissue sarcoma concluded that patients treated in high-volume hospitals less often had macroscopic residual disease.

At an earlier stage, comprehensive incidence estimates were published for all the main primary bone sarcomas in the Netherlands. These incidences for high-grade chondrosarcoma (0.15 per 100,000 European Standardized Rate (ESR)), high-grade central osteosarcoma (0.25 per 100,000 ESR), and Ewing sarcoma (0.15 per 100,000 ESR) are relatively low compared to other cancer types.

We believe that centralization of care towards a bone sarcoma center is sensible given these incidences, regardless of the basis of authorization or government inference. In our study, we reproduced the availability of a bone sarcoma center for bone sarcoma patients based on the number of inhabitants of the represented country. A major increase in the adherence per bone sarcoma center could result in a low referral and treatment percentage, with Turkey and Ukraine as an example as shown in Table 1. A possible explanation could be the increased geographical dispersion in the less populated areas of these big countries.

The ECCO expert group recommends that at least 50 bone sarcoma patients are treated in a bone sarcoma center every year. This threshold is based on guidance from the British National Institute for Health and Care Excellence (NICE). Conversely, the authors state that this threshold of bone sarcoma in 50 patients every year is dependent on referral patterns and expertise distribution. Bone sarcoma patients are defined by the ECCO as patients with chondrosarcoma, Ewing sarcoma, and osteosarcoma. Furthermore, very rare entities as undifferentiated bone sarcoma, chordoma, and giant cell tumor of bone are defined as bone sarcomas by the ECCO. Interestingly, the actual exposure of a bone sarcoma center could be calculated based on our data. A calculation could be made in which the combined incidence for high-grade chondrosarcoma, high-grade central osteosarcoma, and Ewing sarcoma (0.55 per 100,000 ESR) is matched with a minimum exposure of 50 bone sarcoma patients for a single bone sarcoma center every year. This is roughly four patients per month. Based on the ECCO recommendation, a single bone sarcoma center should have a minimal adherence of around 9 mm inhabitants to match the exposure of 50 bone sarcoma patients. Based on our study, this exposure can only be matched by bone sarcoma centers in the United Kingdom, Turkey, and Ukraine. However, as mentioned earlier regarding Turkey and Ukraine, more inhabitants per bone sarcoma center could result in a low referral and treatment percentage of bone sarcoma patients, which seems undesirable. Based on our study, the effects of centralization could not be assessed. Therefore, the optimal size for a bone sarcoma center is not known at present. We believe that the participating bone tumors centers in our study provide excellent bone sarcoma care. The recommendation of 50 bone sarcoma patients per year is based on existing evidence as stated in the ECCO article with a reference to the 2006 NICE guidance document. In this guidance document, the authors refer to studies from the United Kingdom and Sweden, which conclude that treatment of a bone sarcoma in a specialist center is preferred, without notice of a minimum threshold for treatment per year. This suggests that the treatment threshold for a bone sarcoma center of 50 bone sarcoma patients per year is not evidence-based. We believe that the treatment threshold for a bone sarcoma center per year for adequate treatment of their patients is not known at this moment. To evaluate this, a comparative study between differently sized bone sarcoma centers regarding survival in high-grade bone sarcoma patients could be a next step. This should give more clarity about the actual effect of centralization of care on survival. Although the treatment threshold is not known, we think that a minimum treatment threshold of at least one bone sarcoma patient every month in a single bone sarcoma center is desirable. This preserves the available expertise of the multidisciplinary team. Reasonably, bone sarcoma centers with little adherence could benefit from a national bone tumor board for extensive case evaluation including classification and advice for treatment from a team with more experience.

A national registry is the basis for adequate monitoring and reporting of outcomes. Furthermore, a complete national registry could provide valuable and comparative big data for collaborative research, which is needed with the given low incidences for high-grade bone sarcomas. This is emphasized by the previously published collaborative EMSOS studies for several rare entities. In our study, the effect of evaluation of care using a national registry was not investigated. Still we think that better evaluation of care, as one can do with a registry, provides essential information to improve quality of care and outcome for bone sarcoma patients.

In conclusion, we believe that centralization of care towards a bone sarcoma center should be mandatory. The optimal size for a bone sarcoma center in terms of patient adherence is not known at this moment. Furthermore, a national registry is essential for the adequate storage and reproduction of oncological data.

**Acknowledgments**

We would like to acknowledge as well as thank the EMSOS study group for participating and thereby facilitating this study.
EMSOS Study Group

Michiel van Oosterwijk JG, Anninga JK, Gelderblom H, Clayton-Jansen AM, Bovee JV. Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma. Hematol Oncol Clin North Am, 2013, 27: 1021–1048.

2. Anninga JK, Gelderblom H, Ficaro E, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer, 2011, 47: 2431–2445.

3. Duchman KR, Gao Y, Miller BJ. Prognostic factors for survival in patients with Ewing’s sarcoma using the surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol, 2015 Apr, 39: 189–195.

4. Duchman KR, Gao Y, Miller BJ. Prognostic factors for survival in patients with high-grade osteosarcoma using the surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol, 2015, 39: 593–599.

5. Allison DC, Canney SC, Ahlmann ER, et al. A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma, 2012, 2012: 704872.

6. Hoe香菇 HT, Haas RLM, Verhofch H, et al. Adherence to guidelines for adult (non-GIST) soft tissue sarcoma in The Netherlands: a plea for dedicated sarcoma centers. Ann Surg Oncol, 2017, 24: 3279–3288.

7. Gelderblom H, Hogendoom PC, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist, 2008, 13: 320–329.

8. Goedhart LM, Ho VKY, Dijkstra SPD, et al. Bone sarcoma incidence in the Netherlands. Cancer Epidemiol, 2019, 60: 31–38.

9. CIA. The world factbook [Internet]. Available from: https://www.cia.gov/library/publications/the-world-factbook/.

10. European Commission. European Reference Networks [Internet]. Available from: https://ec.europa.eu/health/ern_en.

11. Andritsch E, Beishon M, Bielack S, et al. ECOG essential requirements for quality cancer care: soft tissue sarcoma in adults and bone sarcoma. A critical review. Crit Rev Oncol Hematol, 2017, 110: 94–105. https://doi.org/10.1016/j.critrevonc.2016.12.002.

12. Gronchi A, Delrio P, Quagliuolo V, Sandrucki S. The Italian Society of Surgical Oncology (SICO) survey on the minimum requirements of rare cancers referral centers. Updates Surg, 2016, 68: 321–323.

13. Goedhart LM, Gerber JG, Ploegmakers JJW, Jutte PC. Delay in diagnosis and its effect on clinical outcome in high-grade sarcoma of bone: a referral oncological centre study. Orthop Surg, 2016, 8: 122–128.

14. Kim MS, Lee SY, Cho WH, et al. Prognostic effects of doctor-associated diagnostic delays in osteosarcoma. Arch Orthop Trauma Surg, 2009, 129: 1421–1425.

15. Ozaki T, Hillmann A, Hoffmann C, et al. Significance of surgical margin on the prognosis of patients with Ewing’s sarcoma: a report from the cooperative Ewing’s sarcoma study. Cancer, 1996, 78: 892–900.

16. NICE Guidance. Improving outcomes for people with sarcoma [Internet]. Available from: https://www.nice.org.uk/guidance/csg9/evidence/full-guideline-pdf-2189860813.

17. Stiller CA, Passmore SJ, Kroll ME, Brownbill PA, Wallis JC, Craft AW. Patterns of care and survival for patients aged under 40 years with bone sarcoma in Britain, 1980–1994, Br J Cancer, 2006, 94: 22–29. Available from: http://www.nature.com/dofinder/10.1038/sj.bjc.6602885. (accessed 2 April 2017).

18. Bergh P, Gunterberg B, Meis-Kendblom JM, Kendblom LG. Prognostic factors and outcome of pelvic, sacral, and spinal chordosarcomas: a center-based study of 69 cases. Cancer, 2001; 91:1201–1212.

19. Grimer RJ, Gosheger G, Taminiau A, et al. Dedifferentiated chordosarcoma: prognostic factors and outcome from a European group. Eur J Cancer, 2007, 43: 2060–2065.

20. Verdegaal SHM, Bovee JVMG, Pasunriva TC, et al. Incidence, predictive factors, and prognosis of Chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients. Oncol, 2011, 16: 1711–1717. Available from: http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theoncologist.2011-0200.

21. Frezza AM, Csesari M, Baumhoer D, et al. Mesenchymal chordosarcoma: prognostic factors and outcome in 113 patients. A European musculoskeletal oncology society study. Eur J Cancer, 2015, 51: 374–381.

22. Longhi A, Bielack SS, Grimer R, et al. Extraskeletal osteosarcoma: a European Musculoskeletal Oncology Society study on 266 patients. Eur J Cancer, 2017, 74: 9–16. https://doi.org/10.1016/j.ejca.2016.12.016.